
Market Overview and Upcoming Players in Graft vs. Host Disease
Each year, the incidence of transplants is increasing. Consequently, population of patients with Graft-versus-Host Disease (GvHD) is on the rise. This is especially true for chronic GvHD for which the incidence has been recorded as high as 80%. The frontline treatment is dominated by corticosteroids and other immunosuppressants. However, the refractory nature of the disease requires patients to move on to later lines of treatment, which currently are limited.